Gsk Share Discussion Threads

[alibizzle] 13/6/2024 15:27

I have 10k to invest but with overhang and no decision on appeal for a while it might take time for share price to turn and meanwhile other issues may arise . Might go for baleon instead

[pj84] 13/6/2024 07:56

From the above article: -

"GSK now trades at just 10 times forward earnings, compared with AstraZeneca at 19. This is approaching value territory for the group, which has averaged a multiple of 12.5 over the past five years."

...

"Advice Buy
Why Strong drug pipeline, attractive dividend and possible litigation costs already priced in"

[grahamburn] 10/6/2024 20:28

OK - only one case but still positive given the specific references to no payment (read "NOT settled out of court") and the reference to the 16 studies:

Statement: Zantac (ranitidine) litigation - Kasza case

GSK plc (LSE/NYSE: GSK) welcomes the plaintiff's voluntary dismissal of the next Zantac case (Kasza), which was scheduled to start trial in Illinois state court on 10 June 2024. GSK did not settle Ms. Kasza's claim and has not paid anything in exchange for the voluntary dismissal.


Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.


GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.

[tradermichael] 10/6/2024 07:21

GSK has also filed regulatory submissions to extend the use of its RSV vaccine to adults aged 50-59 at increased risk in Europe, Japan and other geographies with regulatory decisions undergoing review. Trials evaluating the immunogenicity and safety of the vaccine in adults aged 18-49 at increased risk and immunocompromised adults aged 18 and over are expected to read out in H2 2024.

[alphorn] 08/6/2024 17:27

Three RSV vaccines out there with Arexvy (GSK), Abrysvo (Pfizer), and Mresvia (Moderna) approved for medical use in the United States.
(Arexvy also approved in the EU?)

[pj84] 08/6/2024 15:33

"American regulator set to approve wider use of GSK’s Arexvy
US Food and Drug Administration is due to authorise a respiratory virus vaccine for adults aged 50 to 59 in a boost to the British pharmaceuticals company"

...

"Arexvy was first approved for use in adults aged 60 and older and is an important part of the revival of GSK’s drugs pipeline."

...

"Arexvy generated sales of £1.2 billion last year and led GSK to upgrade its longer-term financial forecasts, increasing investors’ confidence in the company’s strategy."

...

"GSK has filed regulatory submissions to extend the use of the vaccine elsewhere, including in Europe and Japan. Scientists are also evaluating the vaccine in adults aged 18 to 49. The results are expected in the second half of this year."

[ny boy] 07/6/2024 15:29

Added some more @ 1615p, decent retrace from 1660 area, I’ll have some of those!

[spoole5] 07/6/2024 11:00

What's the worst case scenario here 5bn? Sure already discounted?

[porsche1945] 07/6/2024 10:03

This must be the most pointless share even by dogshxt ftse 100 standards, hasn’t gone anywhere for over 20 years, soso dividend ( below risk free T bills ). If you take inflation into ac even with dividend youre losing 25pc of your capital every ten years😂

[blackhorse23] 06/6/2024 16:20

They raised APH ( alliance Pharma ) to BUY as well

[tradermichael] 05/6/2024 09:42

Despite the increased litigation risk, Conover believes GSK is likely to be successful in its appeal process.

"We expect a high probability of a favourable GSK appeals ruling for a number of reasons," he says.

"These include a federal ruling that didn't allow Zantac plaintiff experts; 16 clinical studies showing no link between Zantac and cancer; the US Food and Drug Administration clearing Zantac to re-enter the market; and recent litigation wins by GSK, including a case in Chicago that was hand-picked by the plaintiffs."

Though he accepts the ruling will create a risk "overhang" for the British pharmaceutical giant over the next twelve months, Conover expects the Delaware court to accept the appeal in the next two months.

[tradermichael] 05/6/2024 09:40

GSK is currently litigating to contain complaints that its heartburn drug Zantac has allegedly caused cancer. But despite a Delaware State Court allowing Zantac experts to give evidence in future cases, Damien Conover, director of healthcare equity research at Morningstar, is holding firm to GSK's Fair Value Estimate of £22.00.

[ny boy] 05/6/2024 08:23

Entering my initial target zone earlier than expected

[dplewis1] 05/6/2024 08:21

Lol. ... HSBC raises target price to 1400p from 1200p.

[dr biotech] 04/6/2024 14:54

I know, and having been to plenty there are staffed by normal hard working decent people. But the FDA still issues plenty of 483s, and there is unfortunately quite a lot of other bad practice about - price gouging etc. Oxycontin etc hasn't helped.

[tradermichael] 04/6/2024 14:24

Except there is no causal link.

"Big faceless pharma" exist to make unwell people better.

[ny boy] 04/6/2024 14:24

1650/1700 this week, the drop looks a tad overdone, defensive qualities too, despite some court drama brewing.

[netcurtains] 04/6/2024 13:41

Thanks guys. Looking good!

[dr biotech] 04/6/2024 12:39

Won't be for a while. GSK are going to appeal the decision to allow a jury case first so it may never come to that. They may also settle.

Big concern is there is a big faceless pharma "raking in billions" vs some very unwell poor people who can't pay their medical bills. Whilst sympathy and emotion shouldn't be part of a decision, it still could be.

[alibizzle] 04/6/2024 12:30

When does the jury court case begin

[dr biotech] 04/6/2024 12:28

Thats it - and thats only a suspected carcinogen. You'd have to take quite a lot for that to cause issues - and if you are taking it large quantities then you'd have some underlying issues anyway

[tradermichael] 04/6/2024 12:10

There is a potential decomposition product which was only observed when a third party carried out an accelerated storage study where they subjected solid ranitidine to unrealistically high temperatures to produce the carcinogen.

[dr biotech] 04/6/2024 10:25

Looking at the details in this case it seemed that the judge thought it should be put to a jury to decide rather than let a judge take a decision. From memory its not API but a side product that may occur during long storage that could cause issues. All pretty tenuous when I looked into it a while ago.

Seems everything these days is someone elses fault and there's "evidence" on the internet to back it up. Its amazing how some people will swallow it and to see how far it goes. Its like Sidney Powell claiming that dominion switched the votes in the last election. Her evidence was an email from a psychic. And that cost fox $1bn.


(EDIT). I've just had a quick look through some of my notes from last time. The side product was found by a lab that tests pharma products for unwanted chemicals - they have some strange methods of looking for them, ie heat and store the product at elevated temperatures that aren't realistic. They recently suggested that some acne products contained dangerous amounts of benzene. This claim was ultimately rejected due to their poor methods. It would be virtually impossible for GSK to sweep side products under the carpet with the amount of data that is generated during the manufacturing process.

[alphorn] 04/6/2024 10:21

It does not help the case if other Pharmas make settlements.

(It was in 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after a cancer-causing substance called NDMA was found in samples of the drug).

[waldron] 04/6/2024 10:19

s2lowner1
4 Jun '24 - 10:14 - 33032 of 33032
0 0 0